IL-1 inhibitors are expected to be clinically beneficial in treating incurable autoimmune disorders, such as SLE and systemic sclerosis, and in managing increased proinflammatory reactions, such as macrophage activation and cytokine release syndromes [182,191]. This evidence concerns the gene IL1A and systemic lupus erythematosus.